Is Omeros Corp halal to invest in?

According to Musaffa's Shariah screening methodology, Omeros Corp (OMER) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Omeros Corp a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Omeros Corp using these criteria to determine its compliance status.

Can Muslims buy shares of Omeros Corp?

Muslim investors may consider investing in Omeros Corp if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Omeros Corp classified as NOT HALAL?

Musaffa determines the Shariah status of Omeros Corp by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Omeros Corp updated?

The Shariah compliance status of Omeros Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Omeros Corp become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Omeros Corp?

You can check the latest Shariah compliance status of Omeros Corp on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

OMER Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 07, 2026

Report Source: 2025 Annual Report

Omeros Corp. Stock Analysis OMER

United States Health Care Small Cap Report: 2025 Annual

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. The company is headquartered in Seattle, Washington and currently employs 175 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The firm's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The firm also has preclinical programs, including an oncology platform for the development of novel therapeutics.

Key Statistics of Omeros Corp (OMER)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$11.80$13.00

Today's Open

$12.86

Volume

3.27M

P/E Ratio (TTM)

52 Week Range

$2.95$17.65

Market Cap

1.06B

Avg. Volume

1.34M

Dividend Yield

Financial Metrics & Statements of Omeros Corp (OMER)

FAQ's for Omeros Corp (OMER)

According to Musaffa’s Shariah screening methodology, Omeros Corp (OMER) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.